|
Faculty
 |
 |
 |
Andrew Kuykendall, MD
Assistant Professor
Moffitt Cancer Center
Department of Malignant Hematology
Morsani College of Medicine
Tampa, Florida |
Stephen T. Oh, MD, PhD
Associate Professor
Department of Medicine
Hematology Division
Department of Pathology & Immunology
Washington University School of Medicine
St. Louis, Missouri | Haris Ali, MD
Associate Professor
Division of Leukemia
Department of Hematology and
Hematopoietic Cell Transplantation
City of Hope
Duarte, California |
Program Overview
Determining the optimal course of action following JAK inhibitor treatment failure/intolerance/disease progression is extremely difficult because there is no standard course of action. Fortunately, research is identifying new agents that appear to be effective either alone or when combined with ruxolitinib in newly-diagnosed and/or progressing patients. In this activity, three experts discuss how new advances and research should be applied in clinical practice. They will focus mainly on updated data presented at the ASH annual meeting.
This program will conclude with a live question and answer session. Don’t miss the chance to ask the experts your questions regarding practice.
Agenda
| 5 minutes |
Overview of Current Treatment Landscape, Goals of Treatment, and Areas of Unmet Needs |
| 15 minutes |
Updates on JAK Inhibitors |
| 15 minutes |
Updates on Combination Therapies |
| 10 minutes |
Updates on Future Directions of Therapy |
| 15 minutes |
Audience Question & Answer Session |
Target Audience
This educational activity is designed for community-based hematologists, hematologist/oncologists and community-based advanced practice providers in hematology/oncology who provide care to patients with myelofibrosis.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Recount data presented at the ASH annual meeting examining ongoing studies focusing on MF treatment
- Identify practice implications from recent clinical data on MF treatment
Accreditation/CE
 |
CME Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
 |
CPE Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-23-009-L01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
|
|
Nursing Credit
MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 23-009-165
|
|
Disclosure
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Planning Committee
Joan Meyer, RN, MHA, Executive Director, and Cassie Rametta, Senior Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
|
Peer Reviewer
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Instructions for Participation and Credit
There are no fees for participating in this activity.
In order to receive credit, all participants must complete the post-test and activity evaluation following the activity. Partial credit will not be awarded for this activity. Participants must receive a minimum score of 70% on the self-assessment to qualify for CE credit.
CME and CNE Credit certificates will be emailed 4 weeks following receipt of completed requirements.
CPE Credit will be awarded upon completion of a self-assessment and evaluation. Participation verification must be completed within 4 weeks of the activity. Your online CPE certificate will be reported directly to CPE Monitor within 4 weeks of receiving post-activity documentation
If you have any questions regarding the content of this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, x114 or [email protected] |
|
|
| Provided by |
|
Supported by educational grants from
Constellation Pharmaceuticals Inc., A MorphoSys Company and Incyte Corporation. |
|
|
|
|
